New Jersey Assembly Bill A4786

New Jersey 2022-2023 Regular Session

• Introduced: 10/17/22
• Refer: 10/17/22

Caption

Requires performance of myeloma screening under certain circumstances.

Impact

The implementation of A4786 represents the state's commitment to enhancing men's health, particularly focusing on a demographic that experiences higher rates of myeloma—specifically African American men, who are noted to have the highest incidence and mortality rates from this disease. By including myeloma screenings as a standard component of annual physicals, the bill aims to facilitate earlier diagnosis and treatment of this often aggressive cancer, potentially improving health outcomes for affected individuals.

Summary

Assembly Bill A4786 mandates that licensed healthcare professionals performing annual physical examinations on male patients include a screening for myeloma, a cancer affecting plasma cells. This legislative measure is in response to alarming statistics reported by the American Cancer Society, which estimates over 34,000 new cases of myeloma and approximately 12,640 deaths from the disease in the U.S. during 2022. New Jersey alone anticipates about 1,060 new cases and 330 deaths from myeloma in that same year, highlighting the need for early detection and increased awareness of this medical condition.

Contention

While the intent of A4786 is to improve health care and outcomes for men at risk for myeloma, its passage may lead to discussions about the role of mandated screenings within the healthcare system, especially in terms of cost implications for patients and healthcare providers. Critics may argue that mandatory screenings could lead to overdiagnosis or unnecessary anxiety for patients, while proponents may counter that the benefits of early diagnosis far outweigh potential drawbacks. Overall, the bill embodies a proactive approach to combating a significant health concern for men in New Jersey.